Norgine to acquire Theravia from Mérieux Equity Partners.

Norgine, a specialty pharmaceutical and consumer healthcare company, agreed to acquire Theravia, an international pharmaceutical laboratory specializing in rare or neglected diseases, from Mérieux Equity Partners, a private equity firm. Financial terms were not disclosed. "This acquisition is a unique opportunity for Norgine to bolster our growth trajectory, as well as our rare disease portfolio. With our strong legacy and proven track record of successfully bringing innovative treatments to patients, we believe we are well placed to ensure the Theravia medicines reach their full potential," Janneke van der Kamp, Norgine CEO.